OptimizeRx Corp — Director's Dealing 2023

Nov 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2023-11-01

Reporting Person: Greco Theresa (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-01	Common Stock	A	18519	—	Acquired	37038	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-01	Stock Option	$8.10	A	35758	Acquired	2028-11-01	Common Stock (35758)	Direct

Footnotes

F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on November 1, 2024, which is the first anniversary of the date of grant.

F2: The stock option vests in three equal annual installments beginning November 1, 2024, the first anniversary of the grant date.